Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryVentura County Tetrabenazine Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Vesicular Monoamine Transporter Type 2 Inhibitors - Tetrabenazine Prior Authorization Policy

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization coverage for brand Xenazine and generic tetrabenazine in adults with Huntington disease chorea, hyperkinetic dystonia, tardive dyskinesia, or Tourette syndrome and related tic disorders when age, diagnosis, and specialist-prescriber criteria are met.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyTetrabenazine Prior Authorization Policy
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateJun 16, 2021
    Next Review DateN/A
    Key ActionObtain prior authorization and document that tetrabenazine is prescribed by or in consultation with a specialist in the condition being treated.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 yearStandard approval duration
    4Clinical indications with authorization criteria
    ≥18 yearsMinimum age
    ≥36 repeatsHuntington disease genetic threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Recommended Authorization Criteria

    Chorea associated with Huntington disease

    Approve for 1 year when ALL of the following are met.

    All criteria

    • Age: Patient is at least 18 years of age.≥18 years
    • Diagnosis of Huntington disease is confirmed by genetic testing, for example an expanded HTT CAG repeat sequence of at least 36.HTT CAG repeat sequence ≥36
    • Specialist prescriber: Medication is prescribed by or in consultation with a neurologist.

    Hyperkinetic dystonia

    Approve for 1 year when ALL of the following are met.

    All criteria

    • Age: Patient is at least 18 years of age.≥18 years
    • Specialist prescriber: Medication is prescribed by or in consultation with a neurologist.

    Tardive dyskinesia

    Approve for 1 year when ALL of the following are met.

    All criteria

    • Age: Patient is at least 18 years of age.≥18 years
    • Specialist prescriber: Medication is prescribed by or in consultation with a neurologist or psychiatrist.

    Tourette syndrome and related tic disorders

    Approve for 1 year when ALL of the following are met.

    All criteria

    • Age: Patient is at least 18 years of age.≥18 years
    • Specialist prescriber: Medication is prescribed by or in consultation with a neurologist.

    Coverage is not recommended for circumstances that are not listed in the Recommended Authorization Criteria.

    Genetic Testing Reference

    Coding
    HTT CAG repeat sequenceAt least 36 expanded repeats

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization and Specialist Involvement

    Prior authorization is recommended for prescription benefit coverage of tetrabenazine. Approval requires the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated.

    Note

    One-Year Approval Duration

    When the applicable authorization criteria are met, approvals for tetrabenazine are provided for 1 year for the listed indications.

    • Chorea associated with Huntington’s disease
    • Hyperkinetic dystonia
    • Tardive dyskinesia
    • Tourette syndrome and related tic disorders

    Clinical Background

    Tetrabenazine is a vesicular monoamine transporter type 2 inhibitor indicated for chorea associated with Huntington disease in adults. The policy also recognizes hyperkinetic dystonia, tardive dyskinesia, and Tourette syndrome or related tic disorders as uses with supportive evidence. Specialist involvement is required because evaluation, diagnosis, adverse-event monitoring, and assessment of long-term efficacy require specialized skills.

    Key Terms

    Tetrabenazine
    DefinitionA vesicular monoamine transporter type 2 inhibitor used to treat chorea associated with Huntington disease in adults.
    Huntington disease
    DefinitionAn inherited neurologic disorder associated with chorea; diagnosis must be confirmed by genetic testing for coverage of tetrabenazine.
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyTetrabenazine Prior Authorization Policy
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateJun 16, 2021
    Next Review DateN/A
    Key ActionObtain prior authorization and document that tetrabenazine is prescribed by or in consultation with a specialist in the condition being treated.
    SourceLink
    On This Page
    Recommended Authorization CriteriaGenetic Testing ReferenceAuthorization and Documentation RequirementsClinical BackgroundKey Terms
    Documentation Required

    Genetic Confirmation Required

    For chorea associated with Huntington’s disease, document that the diagnosis is confirmed by genetic testing, such as an expanded HTT CAG repeat sequence of at least 36.

    Documentation Required

    Age and Specialist Documentation

    Document the patient’s age and the required specialist prescribing or consultation for the applicable indication.

    • Huntington’s disease chorea: patient is ≥ 18 years old; neurologist required.
    • Hyperkinetic dystonia: patient is ≥ 18 years old; neurologist required.
    • Tardive dyskinesia: patient is ≥ 18 years old; neurologist or psychiatrist required.
    • Tourette syndrome and related tic disorders: patient is ≥ 18 years old; neurologist required.
    Denial Risk

    Unlisted Indication or Circumstance

    Coverage of tetrabenazine is not recommended when the circumstance is not listed in the Recommended Authorization Criteria. Criteria may be updated as new published data become available.